One of the largest pharmaceutical companies in the world is partnering up with a publicly traded company in Canada. And they’re aiming to usher in a new paradigm for robotics and artificial intelligence.
What’s happening:
- Telescope Innovations (CSE: TELI) and pharmaceutical giant Pfizer (NYSE: PFE) have entered into a new research collaboration agreement
The big idea:
- The new research partnership will be largely focused on advancing new technological innovation in robotics and artificial intelligence that can be applied to pharmaceuticals, chemistry and drug discovery
Going deeper:
- Telescope Innovations is focused on being one of the few publicly traded companies on the leading edge of self driving laboratories, a concept which merges artificial intelligence and robotic automation to rapidly accelerate the amount of time required to make new discoveries in materials and chemistry
- Telescope and Pfizer have previously collaborated on self driving laboratories, which led to the development of one of Telescope’s flagship products known as DirectInject-LC that is now being distributed globally by Mettler Toledo (NYSE: MTD)
The intrigue:
- Telescope Innovations was recently awarded a grant from the British Columbia Centre For Innovation and Clean Energy for their proprietary technology focused on producing lithium carbonate from saltwater brine
